Astrazeneca Ab

Nps Pharmaceuticals, Inc.

Tomislav Stefanac

Abdelmalik Slassi

Louise G Edwards

Methvin Benjamin Isaac

Tao Xin

David Wensbo

Jalaj Arora

Donald A McLeod

Thomas M Stormann

Martin Johansson

Annika Kers

Alexander Minidis

Karin Staaf

Scott T Moe

Ian Egle

Daryl Lynn Smith

Kenneth Lars Granberg

Peter Dove

Anne O'Brien

Andreas Christer Wallberg

Susan M Sheehan

Karolina Nilsson

Ulrika Yngve

Helena Gyback

Björn Holm

Bradford Van Wagenen

William Michne

Christoffer Osterwall

Mangus Waldman

Karin Oscarsson

John Malmberg

Tau Xin

Alexander Mindis

Johan Malmberg

Mats Nagard

Donald Mcleod

Thomas Stormann

The present invention is directed to compounds of formula I: Wherein Rto R, X and Z are further defined in the description. The invention also relates to processes for the preparation of the compounds and to intermediates used in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

mGluR5 modulators

The present invention relates to new compounds of formula I, wherein P, Q, X, X, X, X, R, R, m and p, are as defined as in formula I, or, salts, solvates or solvated salts thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

Tetrazole compounds and their use as metabotropic glutamate receptor antagonists

The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

MGluR5 modulators I

The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.

Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing compounds of the formula I and to the use of compounds of the formula I in therapy.

Compounds

The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention relates to new compounds of formula I, wherein P, Q, X, X, X, X, X, R, R, R, R, R, R, G, M, M, M, m and n, are defined as in formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

Growing community of inventors

Burlington, Canada

Tomislav Stefanac